Sells BRIUMVI, a drug that slows relapsing multiple sclerosis by destroying B-cells using an antibody engineered for stronger killing power.
What stands out
- Earnings significantly exceed cash generation
At a glance
Sells BRIUMVI, a drug that slows relapsing multiple sclerosis by destroying B-cells using an antibody engineered for stronger killing power.
What this company is and how it runs — written from structure, not news.
TG Therapeutics sells BRIUMVI, a drug that depletes the B-cells responsible for relapses in multiple sclerosis patients, and the drug's potency depends entirely on a specific pattern of sugar molecules — called a glycan profile — attached to a particular region of the antibody during manufacturing. That glycan profile is not added afterward; it is produced by proprietary cell lines under tightly controlled conditions, so the cell lines and the manufacturing process are inseparable from the drug itself. Because every commercial vial must trace back to a validated run of those same cell lines, expanding production means transferring the entire process to a new facility and proving the glycan profile comes out exactly right before a single dose can be sold — which is why manufacturing is the ceiling on how fast the business can grow. The same dependency is also the company's sharpest risk: if the FDA determines that a process deviation has pushed the glycan profile outside its approved specification, there is no alternative source from which the same drug can be released, and the entire commercial supply stops until the hold is lifted.
How does this company make money?
The company sells BRIUMVI directly to specialty pharmacies and hospital systems at a wholesale price. Revenue is recorded when a shipment leaves. The actual net amount received is lower than the list price because of rebates paid to specialty pharmacies and financial assistance provided to patients who cannot afford the drug.
What makes this company hard to replace?
Neurologists who prescribe BRIUMVI have already learned its specific administration protocols and patient monitoring requirements, and switching to a different drug means relearning a different set. Patients moving from another MS therapy to BRIUMVI — or away from it — need new baseline tests and a new dose titration schedule, which takes time and clinical oversight. Specialty pharmacies that handle BRIUMVI have set up cold storage and handling procedures specific to this glycoengineered antibody, and those procedures do not transfer to a different drug.
What limits this company?
Production cannot simply be handed off to a larger factory. Moving manufacturing to a new site or a contract manufacturer requires a full revalidation process where the new facility must prove it can reproduce the exact glycan profile before a single vial can be sold commercially. Until that proof is complete, no additional output can be released.
What does this company depend on?
The company cannot operate without five things: FDA approval keeping BRIUMVI's manufacturing specification valid, specialized mammalian cell culture manufacturing capability to produce the glycoengineered antibody, cold-chain distribution networks that keep the biologic stable during shipping, neurologists actively prescribing BRIUMVI to their patients, and insurance coverage that makes the drug financially accessible.
Who depends on this company?
Multiple sclerosis patients who rely on B-cell depleting therapy would lose access to this specific glycoengineered treatment option if BRIUMVI stopped being available. Specialty pharmacies and neurologist practices that have built their ordering, storage, and administration procedures around BRIUMVI would have to rebuild those workflows for a different drug. Insurance formularies that have already approved BRIUMVI as a covered MS therapy would need to find a replacement to list.
How does this company scale?
Expanding the sales force to reach more neurology practices and new geographic markets is relatively cheap — it is mostly people and travel. What does not scale easily is manufacturing: the specialized cell culture process and the quality controls needed to protect the glycan profile cannot be readily automated or moved to a new facility without risking the consistency that defines the product.
What external forces can significantly affect this company?
Changes to Medicare and Medicaid reimbursement policy for high-cost biologics could shrink the pool of patients who can afford BRIUMVI or reduce the price the company can charge. Approval timelines set by the European Medicines Agency determine when and whether the drug can be sold in international markets. Healthcare consolidation — fewer independent neurology practices as hospitals absorb smaller clinics — reduces the number of separate prescribers the sales force can reach.
Where is this company structurally vulnerable?
If the FDA found that a manufacturing deviation had shifted ublituximab's glycan profile outside the approved specification, it could issue a manufacturing hold or force a recall. Because no other facility is validated to produce the same specification, there would be no alternative source of BRIUMVI while that hold was in effect — the product would simply be unavailable.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations describe the present configuration: a high share of the trailing year's weekly closes were higher than the prior week, the company has reported positive net income in each of the last three annual periods, and the industry-benchmarked TTM operating cash flow margin is in the upper peer range.
Three present-state technical observations co-occur: Parabolic SAR is in its rising-state branch with close above the SAR level, the 14-period weekly RSI is at or above 70, and the recent 10-week ATR sits meaningfully above the prior 10-week ATR. The configuration describes rising-bias SAR, elevated RSI position, and expanding short-window volatility.
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
4 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three observations describe the present configuration: operating income increased year-over-year in each of the last four fiscal years, the 6-year revenue CAGR is positive, and revenue increased year-over-year in each of the last five fiscal years. None of the three observations divides by revenue.
Three observations align: revenue has increased every year over the trailing three years, receivables have increased every year over the trailing four years, and operating cash flow margin is on the industry-benchmarked scale. The picture is concurrent growth in revenue and receivables with peer-relative cash-conversion context.
Two observations describe the retention path: net income as a share of pretax income shows a near-zero effective tax rate, and net income as a share of EBIT shows that interest and tax together consume little of operating profit.
Where is this company structurally exposed?
Two structural observations align: accounts receivable have increased year-over-year across the trailing four years, and receivables are a large share of current assets. Together they describe a receivables-heavy balance sheet whose receivables line keeps growing.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph